Cambridge
Research & Instrumentation, Inc. (CRi), a leader in pre-clinical
and molecular imaging, announced today that it has signed exclusive
agreements to distribute 3DHISTECH’s
full suite of digital slide scanners and software applications in North
America, and the development and distribution of next generation product
offerings that address growing applications in digital pathology. These
agreements expand CRi’s offerings in the rapidly growing digital
pathology market.
“The partnership with CRi will accelerate our growth throughout North
America”
“3DHISTECH’s superior slide scanning and analysis products are a clear
fit with CRi’s focus on providing pathologists and researchers with the
right tools to generate more in-depth and reliable information from
tissue slides,” said George Abe, CRi’s president and CEO. “Digital
pathology, to create, analyze, and manage digital images of glass
microscope slides, has become an important approach to enhancing the
quality and efficiency of pathology laboratory workflow. 3DHISTECH has
developed an outstanding set of digital pathology products for the
market.”
Abe added that digital pathology technologies are providing important
infrastructure for emerging molecular diagnostic approaches based on
disease-related biomarkers that CRi is also advancing with its optical
imaging and analysis systems. CRi’s core technologies are transforming
anatomic pathology from a morphology to a molecular-driven discipline.